Mesoblast Limited (MESO)

Market Cap	709.85M
Revenue (ttm)	7.25M
Net Income (ttm)	-73.06M
Shares Out	114.12M
EPS (ttm)	-0.91
PE Ratio	n/a
Forward PE	833.33
Dividend	n/a
Ex-Dividend Date	n/a

Volume	198,154
Open	6.08
Previous Close	6.00
Day's Range	5.82 - 6.24
52-Week Range	1.61 - 10.24
Beta	2.59
Analysts	Hold
Price Target	27.33 (+339.39%)
Earnings Date	May 23, 2024

About MESO

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, includi...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2004
• Employees: 83
• Stock Exchange: NASDAQ
• Ticker Symbol: MESO

Financial Performance

In 2023, Mesoblast's revenue was $7.50 million, a decrease of -26.54% compared to the previous year's $10.21 million. Losses were -$81.89 million, -10.35% less than in 2022.

Analyst Forecast

According to 6 analysts, the average rating for MESO stock is "Hold." The 12-month stock price forecast is $27.33, which is an increase of 339.39% from the latest price.

Price Target

$27.33

(339.39% upside)

Analyst Consensus: Hold